Vericel posted 3Q17 orthobiologic revenue of US $9.9MM, +19.3% vs. 3Q16, and YTD revenue of $27.8MM, +6.5% vs. the prior year.
3Q17
3Q16
$ Change
% Change
Orthobiologics
$9.9
$8.3
$1.6
19.3%
9Mo17
9Mo16
$ Change
% Change
Orthobiologics
$27.8
$26.1
$1.7
6.5%
This is the company’s first quarter following the discontinuation of Carticel sales in the U.S. The $9.9MM logged is derived entirely from sales of MACI autologous cultured chondrocytes on porcine collagen membrane: a third-gen implant for the repair of symptomatic, full-thickness adult knee cartilage defects.
Leadership estimates the target MACI audience to be about 500 physicians. To date, 440 surgeons are trained on MACI procedures; of those, about half came from former Carticel user and non-Carticel user segments.
Under 10% of the potential patient population is currently penetrated. Medical benefit policies are updated to include MACI, and the number of covered lives is about equal to the number of lives covered by Carticel. Biopsies, an important indicator of adoption and growth, have grown 27% year-to-date, and manufacturing capacity is on-track to be well-covered. With this runway, the company is expanding its salesforce from 28 to 40 reps, who should be trained by the end of 1Q18.
Vericel posted 3Q17 orthobiologic revenue of US $9.9MM, +19.3% vs. 3Q16, and YTD revenue of $27.8MM, +6.5% vs. the prior year.
Q17 3Q16 $ Change % Change
Orthobiologics $9.9 $8.3 $1.6 ...
Vericel posted 3Q17 orthobiologic revenue of US $9.9MM, +19.3% vs. 3Q16, and YTD revenue of $27.8MM, +6.5% vs. the prior year.
3Q17
3Q16
$ Change
% Change
Orthobiologics
$9.9
$8.3
$1.6
19.3%
9Mo17
9Mo16
$ Change
% Change
Orthobiologics
$27.8
$26.1
$1.7
6.5%
This is the company’s first quarter following the discontinuation of Carticel sales in the U.S. The $9.9MM logged is derived entirely from sales of MACI autologous cultured chondrocytes on porcine collagen membrane: a third-gen implant for the repair of symptomatic, full-thickness adult knee cartilage defects.
Leadership estimates the target MACI audience to be about 500 physicians. To date, 440 surgeons are trained on MACI procedures; of those, about half came from former Carticel user and non-Carticel user segments.
Under 10% of the potential patient population is currently penetrated. Medical benefit policies are updated to include MACI, and the number of covered lives is about equal to the number of lives covered by Carticel. Biopsies, an important indicator of adoption and growth, have grown 27% year-to-date, and manufacturing capacity is on-track to be well-covered. With this runway, the company is expanding its salesforce from 28 to 40 reps, who should be trained by the end of 1Q18.
Copy to clipboard 
